acut
graftversushost
diseas
agvhd
import
complic
allogen
stem
cell
transplant
allosct
high
dose
glucocorticosteroid
current
recommend
firstlin
treatment
grade
iiiv
agvhd
result
overal
complet
respons
cr
patient
standard
secondlin
regimen
establish
differ
option
report
includ
antibodi
retrospect
review
outcom
patient
steroidrefractori
sr
agvhd
treat
etanercept
institut
patient
transplant
hematolog
malign
receiv
either
myeloabl
nonmyeloabl
condit
regimen
prophylaxi
gvhd
consist
cyclosporin
mycophenol
acid
acut
gvhd
diagnos
median
day
posttransplant
patient
grade
iii
agvhd
gut
secondlin
treatment
etanercept
start
median
day
initi
firstlin
therapi
overal
respons
rate
cr
patient
pr
patient
median
overal
surviv
initi
treatment
etanercept
day
rang
entir
group
median
overal
surviv
day
rang
day
respond
day
rang
day
nonrespond
p
nevertheless
patient
die
caus
death
progress
gvhd
patient
infect
patient
cardiac
death
patient
relaps
patient
secondlin
treatment
etanercept
induc
respons
sragvhd
gut
appear
associ
poor
longterm
surviv
even
respond
patient
introduct
allogen
stem
cell
transplant
allosct
establish
import
treatment
modal
patient
hematolog
malign
aplast
anemia
inborn
error
hematopoiet
progenitor
cell
nevertheless
major
lethal
nonleth
complic
still
prohibit
broader
applic
allosct
acut
graftversushost
diseas
agvhd
major
caus
morbid
mortal
allosct
high
dose
system
glucocorticosteroid
steroid
current
recommend
firstlin
treatment
grade
iiiv
agvhd
result
overal
complet
respons
cr
patient
howev
likelihood
respond
treatment
decreas
increas
sever
diseas
patient
grade
ii
agvhd
diagnosi
significantli
like
achiev
cr
initi
treatment
high
dose
steroid
compar
patient
advanc
agvhd
prognosi
patient
agvhd
fail
respond
high
dose
steroid
poor
current
standard
secondlin
treatment
steroidrefractori
agvhd
sragvhd
numer
strategi
treat
sragvhd
report
result
disappoint
vari
respons
rate
long
term
overal
surviv
os
tumor
necrosi
factor
alpha
involv
pathophysiolog
agvhd
activ
antigenpres
cell
recruit
effector
cell
caus
tissu
damag
etanercept
recombin
human
tumor
necrosi
receptor
fusion
protein
bind
high
affin
consequ
inhibit
biolog
activ
studi
investig
use
primari
well
secondari
treatment
agvhd
shown
promis
respons
rate
firstlin
combin
methylprednisolon
yield
cr
rate
secondlin
treatment
result
overal
respons
rate
orr
secondlin
therapi
combin
etanercept
daclizumab
show
orr
treatment
multiag
combin
therapi
includ
etanercept
report
induc
respons
patient
base
data
implement
use
etanercept
secondlin
treatment
sragvhd
report
result
retrospect
analysi
patient
sragvhd
treat
etanercept
center
retrospect
studi
allosct
patient
treat
etanercept
sragvhd
erasmu
mc
cancer
institut
januari
april
institut
review
board
approv
transplant
protocol
patient
provid
inform
consent
stem
cell
transplant
data
collect
none
transplant
donor
form
vulner
popul
donor
next
kin
provid
written
inform
consent
freeli
given
accord
underli
diseas
age
patient
receiv
either
myeloabl
nonmyelobl
reducedintens
condit
regimen
condit
intens
accord
bacigalupo
transplant
unmanipul
graft
form
hlaident
sibl
sib
least
b
c
hlamatch
unrel
donor
mud
patient
without
suitabl
sib
mud
receiv
umbil
cord
blood
transplant
case
umbil
cord
blood
ucb
doubl
ucb
transplant
perform
use
two
least
b
match
cord
blood
unit
acut
gvhd
prophylaxi
diagnosi
treatment
respons
criteria
standard
agvhd
prophylaxi
allograft
recipi
includ
cyclosporin
csa
mycophenol
acid
mpa
prodrug
mycophenol
mofetil
mmf
case
hla
match
mud
antithymocyt
globulin
atg
ad
condit
regimen
level
csa
measur
high
perform
liquid
chromatographi
whole
blood
sampl
aim
trough
level
acut
gvhd
grade
accord
modifi
glucksberg
criteria
diagnosi
agvhd
prefer
confirm
histolog
involv
tissu
firstlin
treatment
grade
ii
iv
agvhd
consist
prednisolon
csa
mpammf
grade
agvhd
treat
topic
steroid
steroid
refractori
sr
defin
either
progress
diseas
pd
mix
respons
mr
day
firstlin
treatment
responsest
diseas
sd
day
progress
initi
partial
respons
pr
day
treatment
sragvhd
establish
secondlin
treatment
etanercept
initi
addit
firstlin
therapi
etanercept
enbrel
pfizer
administ
subcutan
twice
weekli
dose
mg
intend
period
eight
week
prophylaxi
patient
includ
val
acyclovir
herp
virus
cotrimoxazol
pneumocysti
jirovecii
least
one
year
transplant
prolong
case
gvhd
patient
sragvhd
treat
etanercept
receiv
addit
antiaspergillu
prophylaxi
voriconazol
furthermor
sinc
august
patient
agvhd
lower
gastrointestin
tract
irrespect
steroid
respons
complaint
bloodi
diarrhea
larg
mucos
defect
endoscopi
receiv
levofloxacin
patient
risk
cytomegaloviru
cmv
epsteinbarr
viru
ebv
reactiv
monitor
quantit
polymeras
chain
reaction
pcr
plasma
treat
preemptiv
accord
local
protocol
cr
defin
resolut
sign
symptom
agvhd
pr
defin
improv
stage
organ
without
progress
organ
mr
defin
improv
least
one
organ
progress
least
one
organ
sd
defin
absenc
improv
pd
defin
progress
one
organ
improv
organ
primari
endpoint
studi
best
overal
respons
rate
cr
pr
start
secondlin
treatment
etanercept
secondari
endpoint
os
toxic
os
calcul
use
actuari
method
kaplan
meier
time
start
secondlin
treatment
etanercept
death
caus
death
classifi
treatmentrel
mortal
trm
relapserel
mortal
characterist
fifteen
patient
treat
etanercept
sragvhd
shown
tabl
median
age
year
rang
year
eleven
patient
male
one
patient
receiv
myeloabl
condit
regimen
consist
cyclophosphamid
x
mgkg
x
gray
gy
total
bodi
irradi
tbi
patient
either
receiv
reduc
intens
condit
ric
cyclophosphamid
x
mgkg
fludarabin
x
tbi
x
gy
nonmyeloabl
condit
nma
fludarabin
x
tbi
x
gy
eleven
patient
receiv
peripher
blood
stem
cell
either
hla
ident
sibl
donor
n
hla
match
unrel
donor
n
four
patient
receiv
cord
blood
cb
deriv
stem
cell
one
patient
develop
lateonset
agvhd
discontinu
immunosuppress
day
posttranspl
patient
gvhd
prophylaxi
onset
agvhd
acut
gvhd
develop
median
day
transplant
rang
day
patient
grade
iii
gvhd
gut
major
involv
second
organ
firstlin
treatment
consist
csa
prednisolon
fourteen
patient
one
patient
treat
high
dose
steroid
combin
mmf
impair
renal
function
prohibit
use
calcineurin
inhibitor
initi
secondlin
treatment
etanercept
secondlin
treatment
etanercept
initi
median
day
rang
day
start
firstlin
treatment
highdos
steroid
grade
organ
involv
agvhd
target
organ
start
etanercept
shown
tabl
highdos
prednisolon
maintain
achiev
object
gvhd
respons
except
four
case
sever
infecti
complic
prompt
earlier
taper
median
number
etanercept
dose
rang
tabl
clinic
signific
infecti
complic
ctcae
grade
grade
requir
system
treatment
occur
patient
includ
bacteri
sepsi
patient
viral
infect
patient
includ
cmv
ebv
reactiv
bk
viru
rhinoviru
coronaviru
invas
pulmonari
aspergillosi
patient
one
patient
experienc
seizur
attribut
csa
rather
etanercept
infecti
complic
shown
tabl
median
os
initi
secondlin
treatment
etanercept
day
rang
entir
group
shown
fig
median
os
day
rang
day
caus
death
progress
agvhd
patient
infect
patient
relaps
acut
myeloid
leukemia
one
patient
cardiac
arrest
patient
half
patient
succumb
infect
ongo
gvhd
consid
contribut
factor
acut
gvhd
import
caus
morbid
mortal
follow
allosct
steroidrefractori
acut
gvhd
particular
associ
poor
prognosi
long
term
overal
surviv
studi
evalu
secondlin
treatment
agent
etanercept
shown
promis
result
overal
respons
rate
perform
retrospect
analysi
small
cohort
patient
treat
etanercept
grade
iii
sragvhd
gut
secondlin
treatment
etanercept
result
encourag
overal
respons
rate
nevertheless
eventu
treat
patient
die
importantli
due
progress
gvhd
opportunist
infect
result
compar
well
recent
prospect
studi
publish
van
groningen
et
al
concern
patient
sragvhd
treat
combin
etanercept
inolimomab
receptor
antibodi
cohort
strikingli
similar
respect
age
agvhd
sever
proport
patient
gut
involv
despit
orr
os
median
day
due
progress
gvhd
seriou
infect
relaps
underli
diseas
pattern
promis
initi
respons
patient
follow
nonrelaps
mortal
nrm
patient
due
either
progress
gvhd
occurr
seriou
infect
particular
compar
well
find
wolff
et
al
prospect
studi
use
etanercept
combin
dacluzimab
receptor
antibodi
patient
sragvhd
cohort
younger
median
age
year
includ
fewer
patient
highstag
involv
gut
although
promis
orr
observ
surviv
disappoint
patient
surviv
studi
howev
report
better
overal
respons
surviv
rate
compar
cohort
patient
kennedi
et
al
retrospect
studi
outcom
patient
median
age
year
sragvhd
treat
combin
atg
tacrolimu
etanercept
without
mmf
report
significantli
higher
orr
os
analysi
patient
less
sever
agvhd
also
includ
sever
gut
gvhd
rang
stage
xhaard
et
al
compar
surviv
infect
rate
patient
receiv
mmf
inolimomab
etanercept
addit
steroid
calcineurin
inhibitor
sragvhd
etanercept
treat
patient
younger
cohort
median
age
year
rang
year
highstag
gut
involv
treatment
respons
rate
etanercept
treat
patient
twoyear
surviv
ci
significantli
differ
among
group
busca
et
al
report
use
etanercept
sragvhd
patient
cohort
compar
well
respect
age
median
yeara
rang
year
heterogen
respect
agvhd
sever
compris
fewer
patient
stage
gut
involv
overal
respons
rate
patient
aliv
median
followup
day
rang
day
public
report
etanercept
salvag
therapi
sragvhd
differ
approach
taper
highdos
steroid
describ
taper
taper
start
day
start
etanercept
wolff
et
al
report
start
taper
onset
respons
like
differ
orr
surviv
rate
observ
studi
compar
present
studi
might
explain
type
grade
gvhd
involv
studi
includ
rel
high
proport
patient
sever
stage
iii
iv
agvhd
bowel
involv
wellknown
advers
prognost
factor
respons
therapi
addit
combin
differ
agent
etanercept
studi
variabl
definit
sragvhd
limit
direct
comparison
result
moreov
interpret
clinic
respons
may
difficult
especi
case
gvhd
gut
irrespect
respons
surviv
rate
rate
signific
infecti
complic
high
report
studi
report
infecti
complic
patient
patient
death
attribut
infecti
complic
risk
opportunist
infect
known
high
sragvhd
due
strong
immunosuppress
regimen
impos
frail
recov
posttranspl
immun
system
agent
particular
associ
high
incid
opportunist
infect
moreov
use
cb
deriv
stem
cell
four
patient
might
contribut
transplant
cb
deriv
stem
cell
particular
associ
delay
immun
reconstitut
therefor
adequ
monitor
prophylaxi
infect
import
studi
invas
aspergillosi
caus
death
patient
die
infect
suscept
aspergillu
known
strongli
increas
gvhd
immunosuppress
therapi
adequ
prophylaxi
hospit
sragvhd
patient
higheffici
particul
arrest
hepa
filter
room
necessari
treatment
antifung
medic
durat
immunosuppress
therapi
warrant
present
studi
one
patient
receiv
antifung
prophylaxi
time
initi
etanercept
thirteen
patient
receiv
voriconazol
one
patient
treat
amphotericin
inhal
elev
liver
enzym
imped
use
voriconazol
despit
prophylaxi
three
patient
develop
invas
mould
infect
first
patient
develop
invas
aspergillosi
despit
amphotericin
inhal
second
patient
prove
voriconazoleresist
aspergillu
third
patient
develop
doubl
infect
voriconazoleresist
aspergillosi
zygomycosi
viral
infect
observ
patient
reactiv
cmv
patient
ebv
patient
one
patient
rapid
rise
ebv
viral
load
accompani
lymphadenopathi
monoclon
bcell
popul
bone
marrow
ebvlymphoprolif
diseas
success
treat
rituximab
combin
reduct
immunosuppress
cmv
monitor
pcr
patient
risk
treat
preemptiv
val
ganciclovir
nevertheless
one
patient
develop
cmvrelat
coliti
preemptiv
treatment
probabl
relat
sever
immunosuppress
state
patient
due
gvhd
immunosuppress
agent
use
episod
septicemia
observ
patient
includ
four
due
gramneg
bacteria
episod
gramneg
septicemia
occur
either
introduct
levofloxacin
caus
less
suscept
strain
conclus
although
secondlin
treatment
sragvhd
gut
etanercept
associ
promis
initi
respons
rate
overal
surviv
appear
poor
mainli
due
progress
gvhd
opportunist
infect
altern
strategi
prevent
treat
sragvhd
urgent
need
prospect
studi
priorit
improv
grim
prognosi
sragvhd
